On the other hand, a recent report suggested that SARS-CoV-2 could exploit IFN-driven gene TMPRSS2 for the upregulation of ACE2 to enhance infection during lung injury.39 Therefore, the side effects of IFN-I should be noted when it is used for the treatment of COVID-19. The gene discussed is TMPRSS2; the disease is COVID-19.